详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis

50| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Peking University Cancer Hospital and Institute, Beijing, China [2]Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China [3]Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China [4]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [5]Fujian Medical University Union Hospital, Fuzhou, China [6]The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China [7]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [8]West China Hospital of Sichuan University, Chengdu, China [9]The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China [10]The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China [11]Fudan University Shanghai Cancer Center, Shanghai, China [12]Nanfang Hospital of Southern Medical University, Guangzhou, China [13]The First Hospital of Jilin University, Changchun, China [14]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China [15]Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia [16]North Shore Hospital, Auckland, New Zealand [17]The University of Texas MD Anderson Cancer Center, Houston, Texas, USA [18]University of Michigan, Ann Arbor, Michigan, USA [19]Monash Health, Monash University, Clayton, Victoria, Australia [20]BeiGene (Beijing) Co., Ltd., Beijing, China

出处：

DOI：

ISSN：

关键词： mantle cell lymphoma overall survival pooled analysis second-line

摘要：

We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second-line versus later-line. Here, we present an updated pooled analysis with a longer follow-up of 35.2 months.Data were pooled from two studies-BGB-3111-AU-003 (NCT02343120) and BGB-3111-206 (NCT03206970) of zanubrutinib in R/R MCL. The patients were divided into two groups based on the treatment line of zanubrutinib: the second-line and the later-line group. The inverse propensity score weighting method was used to balance the baseline covariates between the groups. The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), PFS, and OS rates, objective response rate (ORR), duration of response (DOR), and safety.Among 112 pooled patients, 41 (36.6%) patients received zanubrutinib as second-line and 71 (63.4%) patients as later-line therapy. After weighting, OS was significantly improved in the second-line versus later-line group (HR, 0.459 [95% CI: 0.215, 0.98]; p = 0.044) with median OS not estimable in both groups. The PFS was similar between the two groups (HR, 0.78 [95% CI: 0.443, 1.373]; p = 0.389) but with numerically longer median PFS in the second-line versus later-line group (27.8 vs. 22.1 months). ORR was numerically higher in the second-line versus later-line (88.6% vs. 85.7%), and DOR was similar between the two groups (25.2 vs. 25.1 months). Zanubrutinib showed a similar safety profile in both groups.Zanubrutinib in second-line treatment was associated with significantly improved OS compared with later-line treatment of R/R MCL.© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2023]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 2.9 最新[2023版] 3.9 最新五年平均 2.9 出版当年[2023版] 3.9 出版当年五年平均 4 出版前一年[2022版]

第一作者：

第一作者机构： [1]Peking University Cancer Hospital and Institute, Beijing, China

通讯作者：

通讯机构： [1]Peking University Cancer Hospital and Institute, Beijing, China [*1]Peking University Cancer Hospital and Institute, Beijing, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis

文献详情

相关文献